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Abstract 
The origin and functions of mast cells (MCs) have been debated since their description by Paul Ehrlich in 1879. 
MCs have long been considered ‘reactive bystanders’ and ‘amplifiers’ in inflammatory processes, allergic 
reactions, and host responses to infectious diseases. However, knowledge about the origin, phenotypes and 
functions of MCs has increased substantially over the past 50 years. MCs are now known to be derived from 
multipotent hematopoietic progenitors, which, through a process of differentiation and maturation, form a 
unique hematopoietic lineage residing in multiple organs. In particular, MCs are distinguishable from basophils 
and other hematopoietic cells by their unique phenotype, origin(s), and spectrum of functions, both in innate 
and adaptive immune responses and in other settings. The concept of a unique MC lineage is further supported 
by the development of a distinct group of neoplasms, collectively referred to as mastocytosis, in which MC 









established in mastocytosis and in allergic inflammation. However, MCs have also been implicated as important 
participants in a number of additional pathologic conditions and physiological processes. In this article, we 
review concepts regarding MC development, factors controlling MC expansion and activation, and some of the 
fundamental roles MCs may play in both health and disease. We also discuss new concepts for suppressing MC 
expansion and/or activation using molecularly-targeted drugs. 
Key words: histamine, IgE receptor, KIT, mast cell activation, mastocytosis, tryptase 
Introduction 
Mast cells (MCs) are tissue-resident, 
multifunctional effector cells of the innate immune 
system that can also substantially contribute to 
adaptive immune responses. Historically, MCs were 
described and originally named by Paul Ehrlich in 
1879 based on their unique dye-staining properties 
[1]. Ehrlich also described the blood basophil and 
certain morphologic similarities between both cell 
types. However, the origin of MCs, and their roles in 
health and disease, remained mysteries for many 
decades. Two key clues in defining the functions of 
MCs were the demonstration that MCs contain 
histamine and can bind immunoglobulin E (IgE) [2-6]. 
Based on these observations and subsequent 
preclinical and clinical studies, MCs are now 
recognized as key effector cells in IgE-dependent 
allergic inflammation [3-7]. 
Today, the contributions of MCs to allergic and 
other inflammatory reactions are well established 
[3-11]. MCs express high-affinity receptors for IgE and 
produce numerous biologically active substances, 
some of which are stored in cytoplasmic granules for 
rapid release [2-4]. It is now known that MCs may be 
activated by many different agents. These include 
specific antigens (allergens) through allergen-specific 
IgE and IgE receptors, by certain cytokines, 
anaphylatoxins, certain neuropeptides, and 
exogenous toxins, and also by IgG immune complexes 
and complement, certain drugs, and products of 
bacteria or other pathogens [2-9, 11]. MCs activated by 
such mechanisms can release their granule-stored 
mediators, including histamine. In addition, activated 
MCs may synthesize and secrete many other types of 
mediators, such as lipid mediators, cytokines and 
chemokines, and thereby trigger local and systemic 
reactions [2-7]. Although MC activation is observed in 
a variety of inflammatory, infectious, and other 
reactive conditions, it has been best characterized 
during IgE-dependent allergic reactions. 
Human MCs have the ability to re-granulate 
after degranulation and thereby participate in 
multiple cycles of activation with mediator secretion 
[8]. Moreover, certain MCs resident constitutively 
within tissues have a remarkably long life span, 
ranging from months to years, contrasting with the 
much shorter life span of basophils and other type of 
granulocytes [9-11]. Some MC populations, such as 
those induced in the gut of mice during infections 
with certain parasites, can rapidly expand and then 
drop back to approximately baseline levels upon 
resolution of the infection [9, 12, 13]. Thus, in addition 
to the long-term, relatively stable MC populations 
found in many tissues, shorter-lived populations of 
MCs also appear to exist. These MCs can expand and 
contract in particular sites in response to local 
processes, including parasite infections. 
However, the rapid expansion of MC 
populations in multiple organs, including the skin, 
respiratory system and gastrointestinal tract, is also 
observed in mice, rats and cynomolgus monkeys 
injected with the major mast cell growth factor stem 
cell factor (SCF), also known as KIT ligand [9, 12-14]. 
Upon cessation of SCF injections, the numbers of 
these expanded MC populations can rapidly return 
toward baseline values [12-14]. These findings, along 
with the observations that mucosal MCs are absent in 
T cell-deficient mice, indicate that tissue MC 
populations may be responsive to changes in ambient 
levels of soluble SCF, or, perhaps, to changes in 
membrane-bound SCF or other cytokines. 
In this article, we will discuss the progress that 
has been made over the last decades in addressing the 
origin and functions of MCs in health and disease, 
and regarding their neoplastic expansion. We will 
also discuss current diagnostic and therapeutic 
approaches to diseases involving MCs, particularly 
neoplastic disorders. 
Origin of MCs 
After their description and naming by Paul 
Ehrlich in 1879 [1], MCs were soon identified as 
tissue-resident cells in multiple organs, prompting 
discussions about their origin and functions. It was 
proposed initially that MCs were derived from blood 
basophils or from a local histiocytic progenitor. This 
debate lasted many decades, as no experimental 
model was available to resolve the issue. However, 
approximately 100 years after their discovery, the 
origin of MCs from transplantable hematopoietic stem 
cells was convincingly demonstrated. This was done 
in a series of elegant transfer-experiments (and other 
studies) in mice by Yukihiko Kitamura and his 





colleagues [15-18]. Later, the origin of MCs from 
transplantable hematopoietic stem cells was 
confirmed in humans [10]. In both species, MCs were 
found to develop from immature (CD34+) 
hematopoietic precursor cells when these were 
cultured in the presence of certain cytokines or on 
stromal cells [19-23]. 
Subsequent attempts evaluated whether MCs 
were directly derived from hematopoietic stem cells, 
from a later progenitor, or even from a mature 
leukocyte. However, all attempts to grow human MCs 
from highly purified blood monocytes or blood 
basophils failed, regardless of the cytokines or culture 
conditions employed [24]. Moreover, in colony assay 
experiments, human MCs were found to grow 
preferentially in pure MC colonies or in colonies 
containing MCs and basophil-like cells [24, 25]. Based 
on these and more recent observations a bi-committed 
MC/basophil progenitor cell has been postulated, but 
the existence of such a cell is still under debate. By 
contrast, some MCs were also detected in mixed 
colonies derived from pluripotent stem cells [24, 25]. 
Based on these observations, human MCs were 
considered to derive directly from pluripotent 
CD34+/KIT+ stem cells in various organ systems. Such 
multi-lineage and MC-committed CD34+ stem cells 
are detectable in the bone marrow (BM), peripheral 
blood (PB) and in the peripheral tissues in most 
extramedullary organs [9, 22-27]. 
Based on such observations, most CD34+/KIT+ 
MC progenitors are now considered to originate in the 
BM, to translocate from the BM into the PB, and to 
enter peripheral tissue sites after homing to various 
organs (Figure 1A) [9, 26, 27]. In addition, progenitors 
with the potential to generate MCs have been 
identified in the yolk sac [28, 29] and white adipose 
tissue of mice [30]. These latter observations have 
supported the assumption that BM-independent 
pools of self-renewing stem cells giving rise to MC 
progenitors may also develop in local tissue sites early 
during prenatal development; these cells then can be 
maintained (via the self-renewal capacity of local stem 
cells) throughout the lifetime of the organism (Figure 
1B). 
The phenotypic properties of MC-committed 
progenitor cells have been described in mice and 
humans [22, 26, 27, 31-37]. In humans, these cells 
express CD34, KIT (CD117), the interleukin-3 receptor 
(IL-3R) and CD13, but display only low, if any, 
amounts of FcεRI [31-37]. Later, during MC 
development, MC precursors stop expressing CD34 
and the IL-3R alpha chain (CD123) and start 
expressing higher levels of FcεRI and KIT [27, 34-36]. 
Importantly, MC progenitors display a number of 
adhesion molecules through which these cells may 
enter peripheral (extramedullary) organs and tissues. 
For example, in the mouse, beta7 integrin mediates 
the adhesion needed for transendothelial movement 
of BM-derived MC progenitors into peripheral tissues 
[38]. 
Despite the many new insights into the origin 
and development of MCs, several questions remain. 
First, it is not clear whether human MCs also can be 
derived from pre-formed local pools of CD34+ stem 
cells within extramedullary organs. Such a local pool 
of CD34+ MC precursors might be established early in 
life or even during embryogenesis (Figure 1B). 
Another related question is whether MCs in local 
tissue sites can sometimes emerge from a 
bi-committed progenitor cell, giving rise to MCs and 
macrophages or MCs and other leukocytes. In other 
words, although the direct origin of MCs from 
blood-born mature monocytes has been formally 
excluded [24], it remains unknown whether some 
MCs originate from local bi-committed progenitor 
cells giving rise to MCs and macrophages at local 
tissue sites. In this regard, it is worth noting that MCs 
and macrophages share functional and phenotypic 
similarities and that advanced systemic mastocytosis 
(SM) is often accompanied by chronic 
myelomonocytic leukemia (CMML) [39-42]. On the 
other hand, no association between SM and histiocytic 
tumors has yet been described. Finally, while 
definitive information about the exact relationship 
between human mast cells and basophils remains to 
be ascertained, most available evidence is consistent 
with the conclusion that the mature basophil and mast 
cell lineages are distinct [24, 43, 44]. 
Regulation of MC Differentiation, 
Maturation and Survival 
In the mouse, a number of interleukins (ILs), 
including IL-3, IL-4, IL-9 and IL-10, promote the 
development of MCs from their BM progenitor cells 
(Table 1) [9, 22, 45-48]. However, apart from the 
support provided by the IL-network, development of 
mouse MCs is also regulated by tissue-resident 
stromal cells [9, 20, 21]. In a series of pivotal studies, 
SCF was identified as a major player in stem cell- and 
MC development and survival in the mouse [9, 12, 26, 
49, 50]. Deprivation of MC-cultures of SCF (or of 
SCF-expressing stromal cells) results in MC growth 
arrest and apoptosis [9, 26]. Correspondingly, Sl/Sld 
mice (now designated C57BL/6-KitlSl/Sl-d mice) 
lacking (functional) SCF and W/W-v mice (now 
designated WBB6F1-KitW/W-v mice) lacking a 
functional SCF receptor, KIT, exhibit a MC-deficient 
phenotype [9, 15-18, 26]. 






Figure 1. Development of human mast cells from stem and progenitor cells. A. Development of mast cells from uncommitted bone marrow-derived stem and 
progenitor cells. In adult humans, most hematopoietic stem cells (HSC) and mast cell-committed progenitor cells (cells depicted as containing only one cytoplasmic granule in this 
figure) are considered to originate from the bone marrow (BM) under physiologic (normal) conditions. After leaving the BM, these stem/progenitor cells are detectable in the 
peripheral blood and after homing to various tissues and exposure to stem cell factor (SCF) these cells undergo maturation and develop into mature mast cells. Note that in the 
BM, only a few HSC will become mast cell-committed. This is because, apart from SCF, other hematopoietic cytokines are also present and induce differentiation into other 
(non-mast cell) cell types. B. Stem and progenitor cell evolution and distribution during prenatal development. During embryonal and fetal development, primitive (immature) 
mesenchymal stem cells develop in the yolk sac and give rise to multipotent HSC. Both types of cells may be distributed through the blood stream and can invade other organ 
systems, including the liver, BM and skin (green arrows). Some of these cells may form a local pool of self-renewing HSC in extramedullary organs before birth and may be able 
to maintain local pools of HSC and mast cell progenitors via self-renewal in adulthood. After birth, the largest pool of self-renewing HSC is located in the BM. These HSC can leave 
the BM and can home to extramedullary organs (red colored arrows) where they can undergo mast cell differentiation (blue arrows). However, pools of self-renewing HSC and 
HSC-derived mast cell progenitors may also originate from yolk sac-derived stem cells and may later persist in adults. These cells develop into mast cells in local organs 
independent of the BM. There may be additional trafficking routes followed by certain subsets of HSC and mast cell progenitors homing from one to another organ system 
(dotted line-arrows); however, robust data supporting such HSC trafficking routes in humans are not available. Abbreviations: GI tract, gastrointestinal tract; LNs, lymph nodes. 





Table 1. Effects of cytokines on growth and differentiation of 
mouse and human mast cells 
 Effects on proliferation (p) or maturation (m) of: 
Mouse* Human** 
Cytokine MC precursors MCs MC precursors MCs 
SCF + (p,m) + (p,m) + (p,m) + (m) 
IL-3 + (p,m) + (p,m) + (p) - 
IL-4 + (p,m) + (p,m) +/- (p,m)*** +/- (p,m)*** 
IL-5 + (p,m) + (p,m) - - 
IL-6 + (p) +/- (p,m) + (p) - 
IL-9 + (p,m) + (p,m) - - 
IL-10 + (p,m) + (p,m) - - 
IL-11 - - - - 
IL-12 - - - - 
IL-13 + (p,m) + (p,m) n.k. +/- (p) 
IL-15 + (p,m) + (p,m) n.k. n.k. 
IL-33 + (p) + (p) n.k. + (m) 
GM-CSF + (p) - - - 
NGF + (p,m) + (m) - - 
Abbreviations: MC, mast cell; SCF, stem cell factor; (p), proliferation; (m), 
maturation; IL, interleukin; n.k., not known; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; NGF, nerve growth factor. *In most studies mouse mast 
cell precursors were obtained from the bone marrow and studies on mouse mast 
cells refer to data obtained with IL-3-dependent bone marrow-derived mast cells. 
**Most studies on human MC precursors were performed using cord blood cell 
progenitors, and most studies on mature MCs were performed using isolated 
human lung mast cells, skin mast cells, or mast cells cultured from their cord blood 
progenitors using IL-3, SCF and IL-6. ***Under certain conditions, IL-4 can even 
induce apoptosis in MCs and MC precursor cells. 
 
 
In 1990, human SCF was cloned and found to act 
as a ligand of human KIT [51]. Shortly thereafter, 
recombinant human SCF was found to induce the 
development of MCs from their (CD34+/KIT+) 
progenitor cells in vitro [52-54]. In stromal cells (e.g. 
fibroblasts and endothelial cells) SCF is often 
expressed in soluble and membrane-bound forms and 
can serve as a multifunctional MC regulator. In fact, 
membrane-bound SCF acts as an adhesion/homing 
receptor for KIT+ stem cells and MCs [9, 11, 26]. By 
contrast, soluble SCF, once released from stromal 
cells, acts as a MC chemoattractant and as an 
activation-inducing cytokine [55-62]. 
In line with these observations, administration of 
recombinant human SCF to humans resulted in the 
development of increased numbers of MCs at SCF 
injection sites [63, 64]. In addition, there was evidence 
for local activation of MCs, specifically reflected in 
wheal and flare reactions at the skin injections sites in 
these studies. Moreover, in two participants, systemic 
signs and symptoms suggestive of anaphylaxis 
occurred [63, 64]. All in all, SCF appears to be a 
master-regulator of human MCs, promoting the 
transmigration of circulating MC progenitors into 
tissues, their local development into mature MCs, the 
migration and survival of such mature MCs, and MC 
activation. 
Other cytokines may also trigger MC 
development at certain stages of stem cell 
differentiation [9, 34, 45-48]. In a very early phase of 
human MC development, multi-lineage cytokines 
such as IL-3 may expand the pool of CD34+/KIT+ 
stem- and progenitor cells and thus facilitate human 
MC development (Table 1) [34-36, 52, 65]. A similar 
effect was also described for IL-6 [66-68]. Therefore, 
when applied in early phases of culture, both 
cytokines can promote SCF-induced MC development 
in vitro [34, 36, 52, 65-68]. Similar observations have 
been made in the mouse system. However, 
continuous application of IL-3 promotes the 
differentiation of basophils and other myeloid cells, 
while downregulating expression of KIT and 
counteracting differentiation of MCs [69, 70]. 
Correspondingly, late-stage MC progenitors and 
normal mature, resting human tissue MCs lack IL-3 
receptors [34, 36, 71]. In these later phases of MC 
development, other cytokines, such as IL-4, may be 
involved in the differentiation and maturation of MCs 
[72-74]. In particular, IL-4 has been described as 
triggering expression of chymase, certain adhesion 
molecules, and high-affinity IgE receptors in human 
MC precursor cells [72-75]. Depending on the 
environment and organ, IL-4 may even promote the 
proliferation of maturing human MCs [75]. However, 
IL-4 has also been described as downregulating KIT 
expression and KIT-dependent differentiation of 
human MC precursor cells and causing apoptosis of 
human MC progenitors and of lung MCs that express 
only tryptase (MCT), unless IL-6 is also present [70, 
76-78]. 
As mentioned, many different ILs and other 
cytokines can be involved in MC differentiation, 
maturation, and survival in the mouse. These 
cytokines can trigger the expression of multiple 
proteases in MCs and their progenitors, thus 
influencing the cells’ phenotype, and/or can influence 
expression of molecules that enhance MC survival [12, 
79-82]. It seems likely that all of these cytokines act in 
concert to promote MC differentiation and maturation 
in various tissues and organs [9, 11, 80, 81, 83]. Since 
cytokine-expression depends on the tissue-type and 
pathology of the affected organ, certain MC 
phenotypes appear to be tissue-dependent and 
pre-determined, for example by the cytokine-network 
characteristics of the underlying condition and/or 
pathology [7, 9, 11, 80, 81, 83]. In addition, MC 
phenotypes may change depending on the organ 
system and the local tissue microenvironment [9, 11, 
83-87]. Table 1 provides an overview of the effects of 
cytokines on the development and maturation of 
mouse and human MCs. 
The signal transduction pathways and effector 
molecules downstream of MC cytokine receptors have 
been analyzed extensively and a detailed description 
is beyond the scope of this review. However, a few 





important signaling nodes and effector molecules 
should be mentioned, as these are now also 
recognized as potential targets of therapy. One 
important target appears to be the PI3-kinase/AKT/ 
mTOR pathway [88-91]. Disruption of this pathway is 
associated with a decreased ability of MC precursors 
to develop into mature MCs and also impairs MC 
activation [88-91]. The RAS/MEK/ERK pathway is 
also potentially important for MC development and 
function [92-94]. Finally, the JAK-STAT5 pathway has 
been implicated in KIT-dependent growth and 
survival of MCs [91, 95]. All three pathways may be 
highly active, particularly in neoplastic MCs 
exhibiting the transforming KIT mutant D816V. 
Depending on additional mutations (some of them 
directly affecting these pathways, like oncogenic RAS 
mutations), one, two, or all three of these pathways 
seem to play important roles in oncogenesis and drug 
resistance [91, 95]. 
Among several survival molecules acting 
downstream of AKT, mTOR, RAS or STAT5, members 
of the BCL2 family (such as MCL-1, BAX or BCL-xL, 
and several heat shock proteins, like heme 
oxygenase-1, HSP70 and HSP90) play critical roles in 
the survival of normal and/or neoplastic human MCs 
[96, 97]. Effects of such anti-apoptotic molecules may 
not only explain SCF-dependent survival of normal 
MCs, but also the accumulation of neoplastic MCs in 
patients with mastocytosis [96]. Indeed, MCs in such 
patients express excess amounts of these survival- 
promoting molecules, and pharmacologic inhibition 
of these survival molecules is associated with reduced 
survival and increased apoptosis in neoplastic MCs 
[96]. Table 2 provides a list of critical signaling and 
survival molecules relevant to KIT-dependent growth 
and survival in normal and neoplastic MCs. 
Finally, a number of transcription factors are 
considered to be involved in the development and 
differentiation of mouse MCs, including, among 
others, GATA2, microphthalmia (mi) transcription 
factor (MITF), and STAT5 [98-102]. A role for STAT5 
in the growth of neoplastic human MCs has also been 
postulated [91, 95]. Whether the transcription factors 
GATA2 and MITF also play a role in the development 
or function of normal and/or neoplastic human MCs 
remains unknown. 
MC Deficiency Models: Historical 
Aspects and Recent Developments 
As outlined above, the development and 
differentiation of human or mouse MCs from their 
uncommitted hematopoietic stem- and progenitor 
cells depends largely on the presence of a functional 
KIT receptor and its ligand, SCF. KIT is a tyrosine 
kinase receptor that acts as a facultative onco-protein 
and regulates the growth, differentiation and survival 
of germ cells, hematopoietic stem cells, MCs, 
interstitial (intestinal pacemaker) cells of Cajal (ICCs), 
and melanocytes. In mice, ´loss-of-function´ of KIT 
(for example in WBB6F1-KitW/W-v mice) results in 
macrocytic anemia, a profound MC deficiency, 
deficiency of germ cells, lack of ICCs, depigmentation 
of the skin, and failure of neutrophils to express 
inhibitory leukocyte immunoglobulin (Ig)-like 
receptor B4 [9, 15, 26, 103-105]. Apart from 
Kit-deficient mice, there are a number of additional 
MC deficiency models that implicate specific target 
pathways and molecules [106]. MC deficiency also 
may be due to a lack of functionally active SCF (also 
known as steel factor, SL), for example in Sl/Sld 
(C57BL/6-KitlSl/Sl-d) mice [16, 106]. These mice express 
only the extracellular, non-membrane associated, 
domain of SCF. Another model of MC deficiency is 
based on the lack of a functional MITF [106, 107]. 
MITF is involved in the regulation of expression of 
KIT in hematopoietic stem cells, MC progenitors and 
melanoblasts, and is itself regulated by KIT activity 
[106, 107]. In addition, MITF regulates the production 
of a number of mediators, including specific proteases 
in MCs and MC progenitor cells [108-113]. 
 
Table 2. Critical signaling and survival molecules relevant to KIT- 
dependent growth and survival in normal and neoplastic human 
mast cells 











    
pERK - + + ++ 
pAKT - + + ++ 
pS6 - + + ++ 
pSTAT5  - + + ++ 
pBTK - + +/- +/- 
Survival-related anti- 
apoptotic molecules 
    
BCL-2 +/- +/- + + 
MCL-1 - - +/- ++ 
BCL-xL - - +/- ++ 
BIM - - - - 
BAX  - - - - 
PUMA  - - - - 
NOXA  - - - - 
HO-1/HSP32 - - +/- ++ 
HSP70 - - + ++ 
HSP90 - - + ++ 
Abbreviations: MCs, mast cells; STAT5, signal transducer and activator of 
transcription 5; BTK, Bruton´s tyrosine kinase; HO-1, heme oxygenase 1. 
 
 
Initial studies investigating MC functions in vivo 
principally focused on MC-deficient mice whose MC 
deficiency was due to diminished function of KIT, 
such as in KitW/W-v mice, or decreased expression of 
KIT, such as in KitW-sh/W-sh mice. The MC deficiency of 
KitW-sh/W-sh mice is based on a large genetic inversion 
upstream of the c-kit locus which disrupts corin [114] 





and results in a profound MC deficiency as well as 
other phenotypic abnormalities, including increased 
levels of neutrophils and basophils [115, 116]. Both 
KitW/W-v mice and KitW-sh/W-sh mice develop tissue MC 
populations after adoptive transfer of MCs derived in 
vitro from the hematopoietic cells of the 
corresponding wild type (WT) mice or from other 
normal or genetically-altered mice of suitable strains, 
thus producing ‘mast cell knock-in mice’ [117]. After 
adoptive transfer, such in vitro-derived MC 
populations, which often consist of BM -derived 
cultured MCs (BMCMCs), gradually acquire multiple 
phenotypic characteristics which resemble those 
attributed to the native MC populations in the 
corresponding anatomical sites of WT mice [84-86, 
117]. Accordingly, KitW/W-v mice and KitW-sh/W-sh mice 
engrafted with Kit WT MCs or MCs bearing specific 
genetic abnormalities have been used to investigate 
the functions of MCs and certain MC receptors or 
products in diverse biological responses and models 
of disease [115]. 
However, as detailed elsewhere [117-119], such 
experiments are subject to several admonitions, 
including: 1) the phenotypes and anatomical 
distribution of the adoptively-transferred MCs at 
diverse anatomical sites may not be identical to that of 
the corresponding native MC populations in WT 
mice, particularly after intravenous injection of such 
in vitro-derived MCs [117]; 2) the reality that a 
biological response in KitW/W-v or KitW-sh/W-sh mice can 
be “normalized” after the adoptive transfer of MCs to 
such mice indicates that MCs can express the detected 
function in the context of those mutant mice (which 
have multiple phenotypic abnormalities in addition to 
their profound MC deficiency), but does not by itself 
prove that MCs are necessary for the same functions 
in WT mice; and 3) the limited strain background of 
the KitW/W-v or KitW-sh/W-sh mice used for early studies 
of MC function may have revealed some MC roles 
that are strongly expressed in mice on the C57BL/6 or 
related backgrounds, but may be expressed weakly, if 
at all, on other strain backgrounds, such as BALB/c 
[119]. 
Given such concerns about the general utility of 
KitW/W-v or KitW-sh/W-sh mice for studies of MC 
function, several groups have attempted to generate 
transgenic mice that express MC deficiency by 
mechanisms independent of those reflecting 
abnormalities in KIT or its ligand. As reviewed 
elsewhere [115], a variety of mouse strains have now 
been developed which constitutively or inducibly 
lack, or are deficient in, some or all MC populations 
by KIT-independent mechanisms. While each of these 
more recent models of MC deficiency has 
abnormalities in addition to the MC deficiency (e.g., 
two of these strains have moderately reduced 
numbers of basophils [120, 121]), these non-MC 
abnormalities are less pronounced than those in 
KitW/W-v and KitW-sh/W-sh mice. The availability of these 
newer strains of MC-deficient mice should further 
advance our understanding of the roles of MCs in 
mammalian biology. 
To date, there has been no description of humans 
with a genetically-determined MC deficiency. 
However, humans with a single loss-of-function 
mutation in KIT can exhibit the clinical picture of 
piebaldism, a rare autosomal dominant disorder 
characterized by symmetrical pigment defect 
reflecting a localized lack of melanocytes in the skin 
and lack of melanin in the hair shafts. This condition 
may present as a patch of white hair (poliosis) in the 
forehead and/or a patch of non-pigmented 
amelanotic skin (leukoderma) [122], a pigment 
phenotype much like that of mice with a single 
loss-of-function mutation in c-Kit [9, 15, 106]. 
Although the piebald phenotype also can reflect 
loss-of-function mutations in genes other than KIT 
(e.g., SNAI2 [123]), piebaldism was arguably the first 
genetic transmitted pathology recognized in recorded 
history by the ancient Greeks. In these patients, the 
ability of hematopoietic progenitor cells to 
differentiate into MCs in response to SCF may be 
slightly impaired (P.V., personal observation). 
However, based on the ´mosaic-pattern´ of the defect, 
no complete MC deficiency is found in these patients. 
Although some patients with AIDS or various 
genetically-determined immunodeficiencies may 
exhibit reduced numbers of MCs in the gastro-
intestinal mucosa [124], no other natural or clinical 
model of MC-deficiency has yet been identified in 
humans. 
However, it has been described that patients 
with chronic myeloid leukemia (CML) receiving 
imatinib, a strong KIT inhibitor, for 2 or more years 
can develop a profound MC deficiency [125]. The long 
latency until MC deficiency occurs in these patients is 
best explained by the long time required by MC 
progenitors to develop into mature MCs and the long 
life-span (years) of some populations of mature MCs 
[9, 10, 26, 34, 36]. Given the evidence that the 
development of human tissue MCs from their 
progenitor cells is critically dependent on SCF and 
KIT, it is not unexpected that long-term treatment 
with strong inhibitors of KIT-activation can produce 
MC deficiency. The clinical relevance of such an 
induced MC-deficiency, however, remains to be 
determined. 
Proteomic and Genomic Expression 
Profiling Confirms that MCs form a 





Unique Lineage within the 
Hematopoietic Cell System 
It is generally acknowledged that MCs are 
distinct hematopoietic cells that display a unique 
profile of leukocyte differentiation antigens [40, 43]. 
Since tissue MCs display a number of myeloid 
determinants, these cells are commonly considered to 
be ´myeloid cells´ [40, 43]. Initially, protein profiling of 
human MCs was largely restricted to biochemical 
investigations and antibody-typing. Thus, between 
1989 and 2005, extensive antibody-typing was 
performed to establish the phenotype of primary 
human tissue MCs obtained from various organs [40, 
43, 126, 127]. In all organs tested, MCs were found to 
display substantial amounts of CD9 and KIT (CD117) 
as well as certain myeloid surface antigens, including 
CD13 and CD33. The phenotype of primary tissue 
MCs was also compared to that of blood basophils 
and blood monocytes. These studies revealed that 
many other myeloid cell surface structures, like 
CD11b, CD14, CD15, or CD35, otherwise displayed by 
basophils and/or monocytes, are not expressed, or 
expressed only at trace amounts, on human MCs [40, 
43, 128]. 
All in all, a detailed phenotypic comparison 
between MCs, monocytes and basophils, and their 
respective cell lines was consistent with the 
conclusion that MCs are neither related to basophils 
nor to blood monocytes (Figure 2) [128]. Later 
large-scale genomic studies, transcriptome analyses, 
and proteomic studies confirmed that the mRNA and 
protein expression profiles of MCs are unique and 
distinct within the family of hematopoietic cells 
[129-131]. Finally, KIT mutational studies in patients 
with systemic mastocytosis (SM) confirmed that MCs 
form a distinct cell lineage without a direct 
developmental relationship with basophils or other 
leukocytes [44]. 
The notion that MCs form a separate 
hematopoietic cell lineage defined by specific cell 
surface antigens has major practical and clinical 
implications. First, the unique phenotype of MCs 
enables their detection and their enrichment from 
various tissues [43, 126, 127, 132]. Second, the 
counting and phenotyping of MCs critically 
contribute to the diagnostic work-up of patients with 
suspected SM [133-135]. In this context, it is 
noteworthy that the phenotype of neoplastic MCs in 
patients with SM is aberrant, recurrent, and unique. In 
particular, in contrast to MCs in normal or reactive 
tissues, MCs in SM usually display CD25 and often 
also CD2 and/or CD30 [133-136]. Currently, two of 
these antigens, CD2 and CD25, serve as minor 
diagnostic criteria for SM defined by the World 
Health Organization (WHO) [137-139]. The fact that 
these aberrantly expressed antigens are otherwise 
primarily expressed on lymphopoietic cells, has 
recently re-introduced a discussion about the nature 
and origin of normal and neoplastic MCs and, more 
importantly, re-enforced the concept that MCs form a 
unique hematopoietic cell lineage. 
 
 
Figure 2. Lineage relationships between human mast cells, basophils and 
monocytes based on CD antigen expression profiles. Human lung mast cells 
(MC), the human mast cell line HMC-1, normal blood basophils (BA), the human 
basophil cell line KU812, normal blood monocytes (MO) and the human monoblastic 
cell line U-937 were analyzed using a panel of 90 different CD antibodies provided by 
the Leukocyte Typing Workshops. Based on antibody-reactivities, linkage distance 
analyses were performed (Agis H, et al., Immunology. 1996; 87: 535-43). As expected, 
the linkage distance within the cell lineages examined (primary cells versus respective 
cell lines) is low. Primary basophils and monocytes and the respective lines were also 
found to be related phenotypically. By contrast, however, the phenotype of MC did 
not reveal a close relationship with BA or MO, neither in the cell line context nor in 
primary cells (primary MC vs primary BA). These data suggest that MC and BA form 
two separate (independent) hematopoietic cell lineages within the leukocyte family. 
 
There are also additional antigens that are 
expressed aberrantly on neoplastic MCs, such as the 
IL-3 receptor alpha chain (CD123) [140]. Other cell 
surface antigens, including CD203c and the C5a 
receptor (C5aR) CD88, are usually expressed at higher 
levels on neoplastic MCs in SM compared to normal 
BM MCs [134, 141, 142]. Interestingly, some of these 
receptors are also expressed on ‘reactive (activated) 
MCs’ in various inflammatory conditions. For 
example, in patients with rheumatoid arthritis, MCs 
can express the C5aR CD88 [143]. Even CD25 may be 
detectable in reactive MCs in inflamed tissue sites 
(P.V., unpublished observation). Therefore, these 
surface antigens serve as minor, not major, criteria of 
SM. Table 3 provides a summary of relevant cell 
surface molecules expressed on normal, reactive and 
neoplastic MCs [43, 135, 144]. 
Mediators and Other Compounds 
Produced by Tissue MCs 
MCs contain many functionally defined and 
clinically relevant mediators in their cytoplasmic 
(secretory) granules [3, 4, 7, 145-152]. In human MCs, 
these include, among others, histamine, heparin, 
tryptase, carboxypeptidase, and chymase, which are 





stored in their metachromatic granules (Table 4). 
Other mediators, such as lipids (e.g. prostaglandin 
D2, leukotriene C4, platelet-activating factor, and 
sphingosine-1-phosphate), are primarily produced 
during MC activation. In general, MC-derived 
mediators are classified on the basis of their chemical 
structures and their specific biological functions, as 
well as their locations of storage or origin within MCs. 
Granule-derived mediators are often bound to 
heparin and many of them contribute to inflammatory 
(allergic) reactions [151-153]. Some MC-derived 
mediators, such as heparin, tissue type plasminogen 
activator (tPA), MC proteases and MC-derived 
cytokines (some of which appear to be pre-formed), 
are molecules characteristically associated with local 
tissue repair [154-159]. 
 
Table 3. Cell surface antigens expressed on normal, reactive and 
neoplastic human mast cells 
Cell surface antigens expressed on normal, reactive and neoplastic human 
mast cells  
 Expressed on the surface of: 








LFA-2 CD2 - - +/- +/- -/+ 
AMP-N CD13 + + + + + 
LPS-R-r CD14 - - - - - 
IL-2RA CD25 - - +/- + + 
Ki-1 CD30 - - +/- +/- +/- 
Siglec-3 CD33 + + + + + 
HPCA-1 CD34 - - - - - 
Leukosialin CD43 + + + + + 
Hermes-R CD44 + + + + + 
CLA CD45 + + + + + 
ICAM-1 CD54 + + + + + 
LFA-3 CD58 + + + + + 
LAMP-3 CD63 + + + + + 
C5aR CD88 -/+ + + + +/- 
GM-CSFRA CD116 - - - - - 
KIT CD117 + + + + + 
IL-3RA CD123 - - - - +/- 
L1CAM  CD171 n.k. + +/- n.k. n.k. 
ENPP3 CD203c +/- +/- +/- + + 
FcεRI n.c. + + - + -/+ 
MRGPRX2 n.c. - + - n.k. n.k. 
*Lung mast cells (MCs) from surgical tumor tissue samples and skin MCs from 
inflamed foreskin samples were examined. **Mast cells in patients with ISM and 
MCL usually express the KIT mutation D816V. All data were obtained from the 
available literature. Abbreviations: CD, cluster of differentiation; ISM, indolent 
systemic mastocytosis; MCL, mast cell leukemia; LFA-2, leukocyte 
function-associated antigen-2; AMP-N, aminopeptidase-N; IL-2RA, interleukin-2 
receptor alpha chain; HPCA-1, human precursor cell antigen 1; LAMP-3, lysosomal 
associated membrane protein-3; C5aR, complement component 5a receptor; Ki-1, 
Kiel-antigen-1; CLA, common leukocyte antigen; ICAM-1, intercellular adhesion 
molecule-1; GM-CSFRA, granulocyte-macrophage colony-stimulating factor 
receptor alpha chain; ENPP3, ectonucleotide pyrophosphatase/phosphodiesterase 
3; n.c., not (yet) clustered; n.k., not known. 
 
 
In vitro-derived mouse MCs also can produce a 
wide variety of cytokines, chemokines and growth 
factors [11, 146-150] and some of these products also 
have been detected in isolated mouse peritoneal mast 
cells [11]. While some of these products apparently 
can be stored in certain MC granules, such as tumor 
necrosis factor (TNF) alpha or vascular permeability 
factor (VPF), also known as vascular endothelial 
growth factor (VEGF), the largest amounts of these 
substances are generally thought to be synthesized 
and directly secreted after MCs have been 
functionally activated [11, 146-150, 159, 160]. 
 
Table 4. Selection of biologically relevant mediators that human 
mast cells produce and secrete 
Substance Biologically relevant functions  
Histamine Vasodilation, vascular permeability, endothelial cell priming 
for leukocyte-rolling, neuroendocrine mediator, 
pro-inflammatory  
Heparin Co-factor of ATIII, of tPA and of tryptase, anti-inflammatory 
PGD2 Induces bronchoconstriction, activates endothelial cells, 
induces vasodilation and VEGF production, activates Th2 
lymphocytes, eosinophils and basophils 
Alpha tryptase May promote mast cell activation  
Beta tryptase Fibrinogenolysis, mitogen for fibroblasts and endothelial 
cells, lipid-modifier, degrades VIP, endothelin, fibronectin, 
collagen, calcitonin gene‐related peptide, protease‐activated 
receptor 2, RANTES and eotaxin 
Chymase Lipid-modifier, degrades apolipoprotein B, VIP, fibronectin, 
vitronectin, bradykinin, HGF, SCF, C3a, and thrombin; 
induces smooth muscle cell and endothelial cell apoptosis, 
converts angiotensin (Ang) 1 to Ang 2, and big endothelin to 
endothelin, activates IL-1-beta and TGF-beta-1 
TNF-alpha Endothelial cell and macrophage activation, induces 
apoptosis in smooth muscle cells and other perivascular cells, 
mediator of catabolic processes, tissue inflammation and 
tissue damage 
IL-3 Multipotent growth factor for myeloid cells, expands the 
pool of multilineage progenitor cells in the bone marrow, 
induces the differentiation of basophils, eosinophils, and 
macrophages, promotes activation of (primes) basophils and 
eosinophils 
IL-8 Induces chemotaxis (migration) and activation of 
granulocytes and monocytes, pro-inflammatory and 
angiogenic mediator 
CCL2 Induces leukocyte chemotaxis and activation 
OSM Promotes angiogenesis, fibrosis and tissue remodeling  
VEGF  Promotes angiogenesis and vascular permeability  
FGF Promotes fibrosis and wound healing 
ATIII, anti-thrombin 3, tPA, tissue type plasminogen activator; PGD2, 
prostaglandin D2; VEGF, vascular endothelial growth factor; VIP, vasoactive 
intestinal peptide; RANTES, regulated on activation, normal T cell expressed and 
secreted; HGF, hepatocyte growth factor; SCF, stem cell factor; IL, interleukin; TGF, 
transforming growth factor; TNF, tumor necrosis factor; CCL2, CC-chemokine 
ligand 2; OSM, oncostatin M; VEGF, vascular endothelial growth factor; FGF, 
fibroblast growth factor. 
 
 
By contrast only a few cytokines and chemokines 
have been detectable in resting human MCs. In 
particular, normal human tissue MCs are considered 
to store some preformed TNF-alpha in their granules. 
However, normal human MCs do not express many 
other cytokines unless activated by external stimuli. 
By contrast, after IgE-dependent activation in vitro or 
exposure to activating cytokines such as SCF, human 
(and mouse) MCs can express and release several 
different cytokines, including interleukins (like IL-3) 
and chemokines [146-150, 160]. Most of these 
cytokines and chemokines are also produced in 
neoplastic MCs, where the activating KIT mutant 





D816V acts as a persistent stimulus for cytokine/ 
chemokine synthesis. For example, KIT D816V- 
transformed neoplastic MCs display substantial 
amounts of oncostatin-M (OSM), IL-8 and the CC- 
chemokine ligand 2 (CCL2) also known as monocyte 
chemotactic protein 1 (MCP1), and CCL23 [161, 162]. 
However, other studies suggest that normal human 
MCs, either in the resting state or after activation via 
the FcεRI, do not generate multiple cytokines [129, 
160, 163]. These observations highlight the need for 
additional research to ascertain the ability of normal 
vs. neoplastic human MCs to generate cytokines and 
chemokines under different conditions and states of 
activation. 
Table 4 presents a summary of clinically relevant 
MC-derived mediators and cytokines. A 
comprehensive overview of all these molecules is 
beyond the scope of this article. However, it should be 
emphasized that several MC mediators, such as 
histamine, are clinically important as they contribute 
to the typical signs and symptoms of patients with 
IgE-dependent or independent allergies and patients 
with mastocytosis. Other mediators may be involved 
in tissue remodeling and repair processes, including 
fibrosis and angiogenesis [7, 152, 153, 161, 162]. 
Whether some of the specific signs and symptoms 
observed in advanced SM, such as weight loss (an 
established TNF effect) or fatigue, are triggered by 
MC-derived cytokines (e.g., during cytokine storm) is 
presently unknown. 
Mechanisms Contributing to MC 
Mediator Release and Releasability 
The ability of MCs and basophils to respond to 
IgE-dependent or -independent stimuli (i.e. the cells´ 
“releasability”) is determined by many factors. These 
include genetic and epigenetic effects, the type and 
dose of agonist (e.g., specific allergen recognized by 
the cells’ FcεRI-bound IgE antibodies), the local 
micro-environment, the levels of ambient cytokines 
(which may either directly induce mediators secretion 
or modify the cell’s responses to other stimuli), and 
the underlying disease pathology [164, 165]. The 
features and severity of reactions evoked by MC 
activation depend on additional factors, such as the 
type and amounts of mediators released and the 
number and location of reacting MCs (and other 
immune cells including basophils) involved in the 
response [166, 167]. When MC activation is 
substantial, this can result in systemic anaphylaxis 
and, in certain settings, the criteria for a MC activation 
syndrome (MCAS) may be fulfilled [168, 169]. 
However, MCs also can undergo activation 
chronically or locally in a number of inflammatory 
conditions without clinical signs or symptoms of 
systemic MC activation, so that MCAS criteria are not 
fulfilled [170]. 
In IgE-dependent allergic disorders, IgE-receptor 
cross-linking is usually the critical event that leads to 
mediator release [4-7]. Certain cytokines promote 
such IgE-dependent reactions. In humans, SCF 
augments MC IgE-dependent histamine release 
[60-62]. When applied at higher concentrations 
and/or for longer periods of time (>90 minutes at 
≥100 ng/ml), SCF can directly induce histamine 
secretion in primary human tissue MCs [60-62]. 
Similar effects of SCF have been described in mice in 
vivo [57] and in humans injected subcutaneously with 
recombinant human SCF [63]. In those settings, SCF 
induced degranulation that resembled IgE-induced 
anaphylactic degranulation [57, 63]. However, it is 
worth noting that the activation of MCs by certain 
cytokines can differ substantially from anaphylactic 
degranulation. In particular, ultrastructural analyses 
have shown that the stimulation of MCs with certain 
cytokines results in piecemeal degranulation in which 
vesicles are thought to transport mediators to the cell 
surface in the absence of classical degranulation and 
in which the slow release of mediator substances 
follows. In contrast, IgE-dependent activation is 
usually followed by rapid degranulation and the 
release of stored MC mediators via the process of 
rapid compound exocytosis [171]. 
Apart from SCF and IgE-dependent stimuli, 
many other agonists also induce mediator release in 
human MCs. For example, C3a and C5a induce 
histamine release in human CD88+ skin MCs 
[172-174], and in a small subset of CD88+ lung MCs 
that express both tryptase and chymase (MCTC type) 
[175]. In many other extra-cutaneous organ systems, 
MCs usually lack CD88 and do not respond to C3a or 
C5a unless an inflammatory reaction is ongoing, such 
as in rheumatoid arthritis [143]. In the mouse, genetic 
and MC transfer studies indicate that C3a and C5a, 
acting via the C3aR and the C5aR respectively, can 
directly induce degranulation of skin MCs and that 
the endogenous production of such anaphylatoxins 
may also augment the intensity of IgE-dependent MC 
activation in the skin [176]. 
Several seminal review articles have discussed 
the various biochemical and signal transduction 
pathways that underlie IgE-receptor-mediated, 
cytokine-induced or C3a/C5a-mediated activation, 
degranulation, and mediator release in MCs [2-6, 9]. 
Figure S1 provides an overview of IgE-receptor- 
dependent and KIT-dependent signaling cascades. 
For more details, the reader is referred to the available 
literature. It is important to note that several of these 
activation-linked events and downstream signaling 
molecules are emerging novel targets of therapy for 





allergic (atopic) diseases, mastocytosis and MCAS. 
Heterogeneity and Versatility of MCs 
Several observations suggest that mouse and 
human MCs in various organs have heterogeneous 
phenotypic and functional properties [9, 79-81, 83, 87, 
135, 143, 172-175, 177-179]. Despite earlier 
contributions by William Bate Hardy [179] and others, 
Lennart Enerbäck is often regarded as the first to 
provide a detailed description of MC heterogeneity in 
rodents [177]. He identified two distinct types of MCs 
in rat tissue sections: mucosal MCs (MMCs) and 
connective tissue-type MCs (CTMCs) [177]. 
Compared to CTMCs, MMCs are smaller, more 
variable in shape, and often hypo-granulated. CTMCs 
were also identified as a unique source of heparin. By 
contrast, rodent MMCs contain glycosaminoglycans 
of lower sulfation, no heparin, low amounts of 
histamine, and little or no serotonin [177]. A 
surprising observation was that special fixation 
procedures were necessary to detect MMCs in rat 
tissue sections. Later, MMCs and CTMCs were also 
detected in mice. 
In both species, MMCs and CTMCs display 
specific patterns of MC proteases [180-182]. Notably, 
mouse MMCs preferentially contain mouse MC 
protease (mMCP)-1 and -2, whereas CTMCs express 
mMCP-4, -5, -6, and carboxypeptidase A [180-182]. In 
addition, it was found that the development of MMCs 
and CTMCs is controlled by distinct cytokines, 
including SCF (CTMCs), IL-3 (MMCs), and other 
MC-targeting interleukins [12, 46, 79-81, 83, 182]. 
CTMCs were also regarded as innate or constitutive 
MCs whereas MMCs were thought to represent an 
adaptive MC compartment, which is inducible by the 
tissue microenvironment in response to inflammatory 
processes [183]. 
Subsequent studies revealed that the phenotypes 
of MMCs and CTMCs are, at least in part, reversible in 
certain tissue locations and cytokine milieus, and that 
trans-differentiation between the two types of MCs 
may occur in physiologic and pathologic tissues [81, 
83-87, 182]. In addition, based on the expression of 
various combinations of different MMCPs, MC 
heterogeneity is complex and cannot be fully 
understood based on a simple model predicting two 
major MC subsets (MMCs and CTMCs). Rather, 
increasing data suggest that MCs are functionally and 
phenotypically versatile cells. In fact, MCs may 
change their phenotype (e.g. protease-composition) 
rapidly depending on the cytokines to which these 
cells are exposed, the tissue microenvironment, the 
maturity of the responding MC population, and the 
underlying pathology [81, 83-87, 143, 182]. 
In humans, MC heterogeneity was first 
described on the basis of differential expression of 
neutral proteases in MCs derived from the skin and 
other organs. In particular, it has been reported that 
skin MCs express both tryptase and chymase in their 
secretory granules (MCTC), whereas most MCs in the 
lung and small intestinal mucosa display tryptase but 
not chymase (MCT) [178]. Attempts to relate MCTs to 
mouse MMCs and MCTCs to CTMCs were only partly 
successful, mostly because mixtures of MCTs and 
MCTCs were found in most extra-cutaneous tissue 
sites. 
Human MCs can also be classified based on 
expression of certain surface receptors and responses 
to certain stimuli [143, 172-175]. For example, the 
C5aR CD88 is expressed abundantly on all MCs 
derived from skin (MCTCs) and on the small portion of 
lung MCs that are MCTCs, but not detectably on 
human lung MCTs [174, 175]. Expression of the C5aR 
on MCs may also depend on the underlying disease. 
For example, the C5aR CD88 is expressed on synovial 
MCs in rheumatoid arthritis but not on synovial MCs 
in patients with osteoarthritis [143]. Carboxy-
peptidase A3, which is usually expressed only in 
MCTCs in healthy tissues, is also expressed in 
chymase-deficient MCs in certain inflammatory sites, 
including eosinophilic esophagitis, severe asthma, 
exercise-induced bronchospasm and chronic sinusitis. 
Finally, opioid receptors, including the MRGPRX2 
receptor, are expressed on human skin MCs, but not 
on MCs in other organs [163, 184]. 
To date, the factors and mechanisms underlying 
expression of CD88 and carboxy-peptidase A3 in MCs 
remain unknown. One hypothesis is that chronic 
cytokine exposure or continuous KIT activation 
triggered by a mutation leads to expression of CD88. 
In line with this hypothesis, MCs in patients with KIT 
D816V+ SM constitutively display CD88 [185]. Other 
markers are also expressed on both neoplastic MCs in 
SM and reactive MCs in inflamed tissues. One 
interesting surface marker-antigen is the alpha-chain 
of the IL-2 receptor (IL-2RA), CD25. This antigen is 
usually not expressed on MCs in healthy tissues. 
However, in pathologic tissues and chronic 
inflammatory reactions, MCs may display CD25 (P.V. 
unpublished observation). Again, the factors 
responsible for abnormal expression of CD25 on MCs 
remain unknown. 
Another important observation is that MC 
antigens may be displayed differentially based on the 
cells´ stage of maturation. For example, the high 
affinity IgE receptor, FcεRI, is not expressed on very 
early MC precursors but appears later during MC 
maturation [34-36, 53, 67, 68]. Finally, certain cell 
surface antigens are rapidly expressed, or increase, 
upon IgE-dependent or cytokine-induced activation 





of MCs. Similarly, compared to resting MCs, IgE 
receptor-activated MCs express increased amounts of 
CD63 and CD203c [135, 142]. It has also been 
described that interferon-gamma induces the 
expression of HLA-DR and CD64 (FcγRI) on human 
MCs [186, 187]. Finally, in patients with mastocytosis, 
neoplastic MCs express various cell surface antigens, 
including CD25, CD30, CD32, CD64, CD88, CD123, 
CD203c, and HLA-DR in an augmented or aberrant 
manner [133-136, 138-142]. 
Potential Physiologic and Pathologic 
Role(s) of MCs 
During the past few decades, several attempts 
have been made to decipher the possible physiologic 
roles of MCs, one of the last unresolved riddles about 
these cells. While no definitive solution to this 
quandary has been presented, a number of interesting 
possibilities have been suggested. One evolving 
hypothesis is that MCs are physiologically involved in 
orchestrating tissue repair processes, in a variety of 
settings, through which the evolution of certain 
pathologies can be avoided. This role would therefore 
be similar to that of neutrophils and macrophages in 
combatting bacterial and other infections. In fact, 
during the past 30 years, more and more data support 
the probability that MCs play an important role as 
defense and repair cells during various pathologic 
conditions and related biological processes. Another 
emerging concept is that MCs and their products are 
essentially involved in the innate, and acquired, 
defense against the lethality of animal-derived 
venoms, a concept that has recently been established 
experimentally in mice and may also apply to 
humans. These concepts, and the diverse roles MCs 
may play in the destructive and healing processes of 
various tissues, are discussed in the following 
paragraphs. 
Potential Role(s) of MCs as Defenders 
against Microbes and Toxins 
Several findings point to the possible roles of 
MCs as defenders in certain infectious diseases 
[188-194]. While a complete overview of all proposed 
functions of mast cells in infectious diseases is beyond 
the scope of the current article, we here discuss a few 
important concepts that relate to the role of MCs as 
possible contributors to host defense. One remarkable 
observation was that MC-deficient mice were more 
susceptible to certain fatal bacterial infections, such as 
peritoneal infection and septicemia following cecum 
ligation and puncture [189, 190]. Similar observations 
have been made in other models of bacterial infections 
[116, 188]. It had also been described that the 
protective ‘MC-effect’ depends on the rapid 
availability of MC-derived TNF-alpha, a cytokine 
known to augment the influx of phagocytes into 
inflamed tissue sites [189, 190]. Indeed, exposure of 
endothelial cells to MC-derived histamine and TNF- 
alpha promotes leukocyte rolling, leukocyte adhesion, 
and the consecutive transmigration of phagocytes. In 
the absence of such phagocyte-trafficking, any 
bacterial disease would become potentially life- 
threatening. 
However, other studies performed in MC- 
deficient KitW/W-v and KitW-sh/W-sh mice suggested that 
MC-derived TNF-alpha may actually contribute to an 
adverse outcome in certain severe forms of cecal 
ligation and puncture [116]. More recent data suggest 
that, in the mouse, basophils represent a significant 
contributor to survival in a moderate form of cecal 
ligation and puncture, and that this role may at least 
in part depend on basophil production of TNF-alpha 
[195]. Other studies have shown that bacterial 
antigens directly induce the release of mediators, 
including TNF-alpha, from MCs [191-193]. However, 
it remains unknown how much TNF-alpha can be 
provided by human MCs in reactions such as these. A 
number of additional mechanisms may contribute to 
the ability of MCs in various organs to enhance 
resistance to bacterial infections [188, 194, 196, 197]. 
These mechanisms may include, among others, MC 
activation via Toll-like receptors (TLR)s [194] 
(although TLRs have not been identified on human 
skin MCs by all groups [163]), complement activation 
[196], and activation through endothelin-1 [198]. 
Moreover, both human and mouse MCs have been 
implicated in bacterial phagocytosis [194, 197]. 
On the other hand, several observations argue 
against a major role for human MCs as defenders 
against bacterial infections. First, human MCs are not 
capable of compensating a severe neutropenia to 
rescue septicemic patients, e.g. during high-dose 
chemotherapy (where MC usually survive). Second, 
in patients with imatinib-induced MC deficiency, no 
increase in the rate of total or severe bacterial 
infections has been reported [125]. These observations 
do not totally exclude the possibility that MCs 
contribute to the immunological defense system 
against bacteria or other microbes in humans. 
However, compared to other immune cells, in 
humans the contribution of MCs appears to be less 
important. 
MCs have also been implicated in host defense 
against various parasites. For example, in mice, an 
intact MC system seems to be required for proper 
defense against certain helminth infections, such as 
infections by Strongyloides ratti, Strongyloides 
venezuelensis or Trichinella spiralis [199-201]. In 





addition, mouse MCs may contribute to host defense 
against primary cutaneous infections with Leishmania 
major [202]. 
A similar role of MCs as defenders against 
parasites in humans has not been established to date. 
In this regard, it is worth noting that the physiologic 
and pathogenetic role of MCs in host defense against 
pathogens may have changed during mammalian 
evolution. In mice and rats, MCs may be part of a 
strong defense-system against bacteria, helminths, 
and other pathogens. However, in humans, it is 
possible that these MC functions may no longer be as 
critically required to guarantee host survival. On the 
other hand, evidence favoring a protective role for 
MCs in response to Strongyloides stercoralis has been 
described in non-human primates [203]. 
Finally, MCs have been implicated in the 
etiology of several viral infections. In fact, a number of 
viruses have been reported to be capable of infecting 
human MCs, including the human immunodeficiency 
virus (HIV) [204-206]. MCs are unique among HIV- 
vulnerable cell types in that they appear to only be 
susceptible to infection with R5-tropic HIV for a brief 
period during their ontogeny when they are CD4+/ 
CCR5+/CXCR4+ [204]. It also has been reported that 
IgE-FcεRI interactions enhance the susceptibility of 
these MC precursors to HIV [205]. As these infected 
MCs enter into tissues, mature, and persist, they 
appear to provide a long-lived, inducible, reservoir of 
persistent HIV in tissues. In vivo evidence supports 
this possibility, in that HIV-infected women have both 
circulating precursor MCs and placental tissue MCs 
that harbor inducible infectious HIV even after having 
been treated during their pregnancy with highly 
active antiretroviral therapy (HAART) [206]. Other 
viruses are also reported to infect human MCs. For 
example, the LAD2 MC line and primary human cord 
blood-derived MCs have been infected with human 
rhinoviruses and RSV [207, 208]. In addition, the 
corona virus receptor CD26 is expressed on human 
skin MCs [131]. 
MCs also may be able to contribute to immune 
defense mechanisms against viruses. For instance, 
rodent, monkey, and human MCs are able to detect 
dengue virus (DENV), a single-stranded, positive- 
sense RNA virus, which results in MC activation and 
degranulation [209]. This MC response has been 
linked to the MC-driven recruitment of natural killer 
and natural killer T cells. Similarly, human MCs can 
produce type I IFNs after exposure to double- 
stranded RNA and/or respiratory syncytial virus or 
reovirus type 1, the former via specific interactions 
with TLR-3 [208]. Such observations are consistent 
with the conclusion that MCs can contribute to innate 
immune responses to viral infections in part via the 
production of type I IFNs. 
Recently, MCs and their products also have been 
implicated in the defense of mice against animal- 
derived venoms [210-216]. In fact, several findings in 
MC-deficient, MC-reconstituted, or MC chymase- 
deficient mice indicate that mouse MCs (and for 
certain venoms, mouse MC chymase), can enhance 
the survival of mice challenged for the first time with 
the venom of the honeybee, several snakes, a lizard, or 
two scorpions [210, 212, 215]. As a consequence, the 
venom-induced tissue damage and the resulting 
death of the host, are significantly ameliorated [210, 
212, 215]. In the case of honeybee and Russell’s viper 
venoms, IgE-dependent MC activation can further 
enhance resistance to the lethality of these venoms in 
mice [213, 215]. Moreover, zebra fish embryos were 
used to assess the toxicity of snake venoms treated 
with human MC proteases [217]. It was determined 
that human MC tryptase-ß, but not human MC 
chymase or CPA, could reduce the toxicity of the 
venoms of six poisonous snakes [217]. Taken together, 
this evidence indicates that MCs, MC proteases, and 
IgE may play important protective roles against the 
serious and indeed fatal, effects of animal-derived 
venoms. However, so far, no broadly applicable 
therapeutic approach has been developed using MC 
proteases. 
Potential Role of MCs as Repair Cells in 
IgE-Dependent Allergic Reactions 
A number of observations point to important 
‘repair-roles’ of MCs during allergen-induced 
anaphylaxis [210, 218-220]. First, MC-derived 
proteases have been described as degrading several 
different allergens into inactive fragments [218, 219]. 
Moreover, MC-derived proteases have been reported 
to degrade IgE [220]. The functional consequence of 
this MC-derived protease activity would be a 
disruption of the allergen-induced tissue damage. All 
of these data point to important biological feedback 
mechanisms during human allergic reactions in which 
MCs and MC-derived products can help to limit the 
local and systemic reactions to allergens. In line with 
this concept, MC-derived proteases can also degrade a 
number of cytokines, chemokines, and vasoactive 
peptides into inactive fragments. 
Potential Role of MCs as Repair Cells in 
Thromboembolic Disorders and Wound 
Healing 
Several biochemical and functional studies in 
humans and other species suggest that MCs represent 
the major source of heparin [9, 154, 158, 221]. It has 
also been reported that MC-deficient KitW/Wv mice 





develop more severe thromboembolic events after 
India ink injection compared to their normal 
littermates, and that injection of heparin can rescue 
these mice from fatal thromboembolic events [222]. In 
addition, human MCs are a unique source of 
non-complexed tissue-type plasminogen activator 
(tPA) [157]. Whereas in many other cell types, tPA is 
expressed and released together with its natural 
inhibitors (PA inhibitors = PAIs) and in the absence of 
heparin, MCs produce and release un-complexed 
(active) tPA together with its stabilizer and activator, 
heparin [157]. In addition, it has been found that MCs 
accumulate in areas of thromboembolism, especially 
around thrombosed vessels [223], and that 
thrombin-activated endothelial cells express and 
release soluble SCF, which in turn attracts MCs 
(Figure S2) [224]. 
These observations support the hypothesis that 
MCs can act as major repair cells in thromboembolic 
disorders, and that in physiologic tissues MCs may 
even be integrated in a prophylactic repair system 
that counteracts thromboembolic events [157]. Other 
studies have shown that patients with clonal MC 
disorders may suffer from a bleeding tendency, and 
that in these patients, hyper-heparinemia and 
sometimes even hyperfibrinolysis (caused by elevated 
tPA) may be detected [225-228]. 
However, several questions remain. For 
example, it remains unknown which triggers cause 
liberation of heparin and tPA from MCs in patients 
with MC disorders. It also remains unknown whether 
MC-derived heparin and tPA can indeed prevent 
local thromboembolic events. Finally, no increase in 
thromboembolic events has been observed in CML 
patients receiving life-long imatinib, although these 
patients develop a MC deficiency [125]. This 
observation suggests that other cells and mechanisms 
can counteract thrombosis. One possibility is that 
basophils may counteract some of the effects of a MC 
deficiency. 
MCs have also been implicated as repair cells in 
wound healing [155, 156, 229-232]. This hypothesis is 
based primarily on the observation that MCs can 
produce several important repair molecules, 
including heparin, proteases, and angiogenic 
cytokines, such as VEGF, fibroblast growth factor 
(FGF) and IL-6 [155, 156, 159, 229-231]. In addition, 
MCs represent a potentially rich source of 
oncostatin-M (OSM), IL-8 and CCL2 [161, 162]. In 
several experimental models, there is evidence that 
MCs indeed may contribute to wound healing 
[229-231]. However, an unequivocal role of MCs in 
wound healing could not be confirmed in all of the 
model systems examined [232, 233]. 
Possible Role of MCs in Atherosclerosis 
and related Cardiovascular Diseases 
Several observations in experimental animals 
and in man suggest that MCs may play an important 
role in the evolution and progression of 
atherosclerosis [234-249]. Early studies revealed that 
activated MCs can support the generation of 
cholesterol-filled macrophages (foam cells) which is 
typical finding in atherosclerosis [234]. 
Mechanistically, the apolipoprotein B-100 (apoB-100) 
component of low-density lipoprotein (LDL) particles 
binds to the heparin proteoglycan component of 
exocytosed MC granules. Subsequently, MC granule- 
derived chymase can degrade apoB-100, thereby 
inducing fusion and tight binding of the LDL particles 
to the granules [236]. Ultimately, the LDL-loaded 
granules are phagocytosed by macrophages, thereby 
leading to cholesterol accumulation in these cells [234, 
235]. MC granules can also facilitate uptake of LDL by 
smooth muscle cells and thereby promote their 
transformation into foam cells [238]. Chymase and 
tryptase were also later found to degrade the 
apolipoprotein A-I component of high-density 
lipoprotein (HDL) [243]. This renders the HDL 
particles unable to remove cholesterol from 
macrophages, thereby accelerating cholesterol 
accumulation and foam cell-formation in the arterial 
wall [243]. 
By immunohistochemistry, MCs containing 
tryptase and chymase have been detected in the 
normal intimal layer of healthy human aortas, as well 
as in the fatty streaks and vulnerable shoulder regions 
of atheromas in atherosclerotic aortas [237]. 
Moreover, studies in human coronary arteries 
revealed the accumulation of activated MCs at the 
actual site of erosion or rupture of the culprit coronary 
plaque that was responsible for an acute coronary 
syndrome or myocardial infarction [240, 241]. 
Mechanistic insights into the possible roles of 
MCs in plaque erosion and rupture have also been 
obtained from in vitro culture experiments. In these 
studies, human MC-derived proteases were found to 
degrade the pericellular matrix of endothelial cells 
and, together with TNF-alpha, induce their apoptotic 
death [245, 247]. This process is known to lead to 
de-endothelialization of the plaque and thus to plaque 
erosion. Moreover, MC-derived proteases can 
degrade the pericellular matrix of smooth muscle 
cells, with apoptotic cell death resulting from loss of 
matrix-derived (external) survival signals [242]. Loss 
of these collagen-producing cells may in turn result in 
further thinning of the collagenous cap of the plaque, 
thereby increasing the risk of plaque rupture [244]. 
Thus, MC-derived proteases may significantly 





contribute to the erosion and rupture of an 
atherosclerotic plaque, both by directly degrading 
pericellular matrices and by facilitating degradation 
of the extracellular matrix via activation of matrix 
metalloproteinases [246]. 
Finally, MCs and their products have been 
implicated in inflammatory processes that trigger and 
sustain atherogenesis [249]. All of these observations 
point to potentially important roles of arterial MCs 
and their inflammatory products in cholesterol 
accumulation in the vessel wall and in plaque 
vulnerability and thus in the progression of 
atherosclerosis. In addition, MC-engraftment of the 
meninges of genetically MC-deficient KitW/Wv mice has 
provided evidence that meningeal MCs can worsen 
stroke pathology in that species, perhaps in part 
through the release of IL-6 [250]. Supplemental Figure 
S3 shows some potential mechanisms by which 
activated MCs may contribute to various stages of 
atherogenesis. 
However, several questions remain concerning 
the role of MCs in atherosclerosis. First, systemic 
disorders characterized by a marked chronic 
activation of MCs, or increases in MC numbers, such 
as atopic disorders, severe allergies or mastocytosis, 
are not known to be associated with an increased risk 
of atherosclerosis, myocardial infarct or stroke. In 
addition, multi-kinase inhibitors targeting KIT lead to 
MC deficiency [125] but cannot protect the individual 
from the development of atherosclerosis. Indeed, 
some of these kinase blockers (nilotinib and 
ponatinib) promote atherosclerosis and the 
occurrence of thromboembolic events [251]. On the 
other hand, the mechanisms through which these TKI 
promote atherosclerosis are not well understood and 
may involve several different cell types and 
molecules. Moreover, imatinib induces MC deficiency 
but does not promote the development of 
atherosclerosis in patients with CML [125]. 
MCs have also been proposed as providing some 
protective functions in the context of atherosclerosis. 
First, MCs provide heparin together with un- 
complexed (PAI-free) tPA [157], a ‘master-cocktail´ 
that is used clinically to treat patients with acute 
arterial occlusion such as myocardial infarction or 
ischemic stroke. Moreover, heparin released from 
activated MCs in atherosclerotic lesions may restrict 
the development of a platelet-rich arterial thrombus 
on the de-endothelialized (eroded) surface of an 
atherosclerotic plaque. MCs also provide several 
additional repair molecules, such as FGF, VEGF, 
OSM, or IL-8 [155-159, 161, 162]. These MC-derived 
repair molecules may contribute to neo-angiogenesis 
and re-perfusion of ischemic organs (after infarction) 
as well as re-canalization of thrombosed vessels [157]. 
From these observations, the hypothesis has 
been raised that MCs may exert both pro-atherogenic 
and anti-atherogenic activities, as well as both pro- 
and anti-repair effects, during ongoing 
atherosclerosis. In reality, the net effect of MCs and 
MC-specific effector-molecules may largely depend 
on additional factors, including the involved vessel 
site and the stage of atherosclerosis. For example, the 
fibrinolytic and fibrinogenolytic activities of MC 
proteases (tPA, tryptase) may counteract 
atherosclerosis and related vascular events in small 
and large arteries, at both early and later stages of 
atherosclerosis. On the other hand, the effects of these 
molecules may also be fatal, for example when the 
thinned fibrous cap of an atheroma ruptures. Table 5 
summarizes the potential harmful and protective 
effects of various MC products in atherosclerosis. 
 
Table 5. Potential contributions of mast cells (MCs) and their 
products to biological processes relevant to the development of 
atherosclerosis 
Effects MC mediators involved 
A. Proatherogenic effects  
Proinflammatory effects in the vessel 
wall 
TNF-alpha and other MC-derived 
cytokines 
Recruitment of leukocytes/phagocytes 
into the vessel wall 
Histamine, MC-derived cytokines 
(TNF-alpha and others) and chemokines 
(CCL2, IL-8, others) 
Modification and cellular uptake of LDL 
by macrophages and smooth muscle 
cells consecutive foam cell formation 
Tryptase and chymase as well heparin 
Modification of HDL molecules into 
pathologic species that are no longer 
capable of mobilizing cellular cholesterol 
Tryptase and chymase 
Endothelial cell and smooth muscle cell 
death with subsequent plaque rupture 
MC proteases and TNF-alpha 
Leakage and disruption of microvessels 
in neovascularized plaque areas 
Histamine, tryptase and chymase 
B. Protective effects and repair functions 
Thrombolysis: degradation of fibrin  
and fibrinogen 
tPA (fibrin-degrader) and uPAR; 
Tryptase (fibrinogen-degrader); Heparin 
(co-factor for tPA, tryptase and 
anti-thrombin III) 
Protection of endothelial cell layers  
and vessel wall integrity 
Tryptase (endothelial cell survival) and 
angiogenic cytokines (VEGF, CCL-2, 
IL-8, others) 
Neovascularization of hypoxic regions  
in atherosclerotic plaques 
Angiogenic cytokines (VEGF, FGF) 
Abbreviations: tPA, tissue type plasminogen activator; VEGF, vascular endothelial 
cell growth factor; FGF, fibroblast growth factor. 
 
Role of MCs as Inflammatory Effector 
Cells in Allergic and Immunologic 
Diseases 
Previous reports have described the pivotal roles 
of MCs in IgE-dependent and IgE-independent 
inflammatory reactions [2-6]. Although a detailed 
review cannot be provided in this article, we should 
note that the key event in such reactions is the release 
of pre-formed granule-derived and newly generated 
pro-inflammatory and vasoactive mediators, 
cytokines, and chemokines [2-7, 145-150]. These 





mediators and cytokines are major triggers of 
immediate and late-phase reactions and thus of the 
clinical symptoms in allergic disorders. Depending on 
many factors, most of which regulate the releasability 
of MCs (and basophils), the reactions and symptoms 
range from mild to severe or even life-threatening 
[164-169]. 
However, as mentioned, MCs can also be 
involved in regulatory feed-back mechanisms that can 
help to limit allergic reactions and symptoms 
[210-212, 218-220]. Desensitization against IgE- 
dependent and IgE-independent stimuli also has been 
described [252-254]. Many of these mechanisms may 
also apply in patients with systemic mastocytosis 
(SM), where the excessive number of MCs results in 
an increased risk for life-threatening anaphylaxis in a 
subset of patients. However, many patients with SM 
maintain a clinically stable course without any 
mediator-related symptoms, so that the hypothesis 
has been raised that their neoplastic MCs may be less 
responsive to IgE-dependent and other stimuli 
through desensitization phenomena and other 
negative-feedback mechanisms [255]. 
On the other hand, many patients with SM suffer 
from recurrent systemic anaphylaxis or even MCAS 
[167-169]. In these patients, as well as in those with 
severe allergies (without SM), the regulatory 
mechanisms described above may have been 
bypassed or are too weak to keep the reaginic 
proinflammatory machinery under control. Recent 
data suggest that patients with severe allergy 
symptoms, or those with mastocytosis and severe 
symptoms, may have extra copies of their alpha 
tryptase gene, a genetic condition called hereditary 
alpha tryptasemia (HAT) [256, 257]. However, not all 
of these HAT patients have severe symptoms and in 
many cases, the exact mechanisms that cause severe 
anaphylaxis in SM and/or MCAS remain unknown. 
Regarding therapy, patients with severe MCAS are 
treated symptomatically with drugs targeting MC 
mediators or their receptors, such as histamine 
receptor blockers, MC-stabilizing drugs and other 
anti-allergic medications. In severe forms, antibodies 
targeting IgE, such as omalizumab, may be 
considered. 
Until approximately 1980, MCs were primarily 
regarded as key effector cells of allergic reactions. 
However, since then MCs and their mediators have 
been implicated in various other inflammatory 
conditions and immunologic disorders [7, 9, 143, 150, 
258-264]. For example, MCs have been described as 
contributing to pro-inflammatory reactions and 
processes in patients with various systemic auto- 
immune disorders [58, 143, 258-264]. While a complete 
overview of the MC´s potential involvement in these 
disorders is beyond the scope of this article, we wish 
to emphasize one of the most prominent and 
important examples, the impact of MCs on the 
pathogenesis and evolution of rheumatoid arthritis 
(RA). 
Earlier studies had shown that MCs are 
detectable in the inflamed synovial tissue of the 
affected joints in patients with RA and that cytokines, 
such as TNF-alpha, which can be derived from MCs 
and other participants in these disorders, play a 
pivotal role in the pathogenesis of the disease 
[258-261]. TNF-alpha and other (potentially) MC- 
derived cytokines have also been implicated in the 
recruitment and activation of leukocytes into the 
inflamed joints in RA [258]. Subsequently, SCF 
produced by activated synovial fibroblasts and other 
local cells was described as attracting and activating 
MCs, thereby providing a mechanism through which 
MCs accumulate and release their cytokines in 
synovial areas in RA [59]. 
However, other MC agonists, such as C3a and 
C5a, as well as IgE and other immunoglobulins, may 
also be involved in MC recruitment and activation in 
RA [143]. Other studies have shown that MC-derived 
proteases play a crucial role in the pathogenesis of RA 
[262, 263]. For example, among several different 
effects on local effector cells of RA, MC-derived 
tryptase can augment the survival and activation of 
local (synovial) fibroblasts [263]. In addition, MC- 
derived proteases may augment autoimmune 
responses in RA [262]. 
The most critical MC-derived cytokine in RA 
appears to be TFN-alpha. Since this cytokine (which 
can be derived from MCs and other cell types) can 
activate synovial cells to produce collagenase, a key 
enzyme that can induce destruction of cartilage, 
antagonists of TNF-alpha have indeed been shown to 
have beneficial effects in this disease [265]. Other 
therapeutic attempts have aimed at the direct 
suppression of MC growth or MC activation in 
patients with RA [260]. However, to date, no robust 
therapeutic concept focusing solely on the MC 
compartment has been described in the context of RA 
or other autoimmune disorders. Also of note, recent 
work with both two types of MC-deficient mice and 
human synovium, has implicated MCs, and 
IgE/FcεRI and Syk, in the development of 
osteoarthritis [266]. 
Potential Role of MCs in Tumor 
Development and Tumor Surveillance 
A number of different studies have pointed to 
several potential roles MCs may play in tumor 
development and/or tumor surveillance [267-271]. In 
fact, depending on the tumor type, tissue of origin, 





experimental model, and biologic context, MCs have 
been thought either to promote or inhibit the 
development of a neoplasm [267-271]. The 
mechanisms underlying this proposed dual role of 
MCs is not completely understood. However, MCs 
can produce a number of substances that may 
contribute to tumor or leukemia cell proliferation and 
survival (e.g., growth factors), tumor cell 
redistribution and metastasis (e.g., vasoactive 
substances, chemotactic factors, adhesion receptor- 
inducers) and/or modulation of the tumor-related 
microenvironment (e.g., angiogenesis-promoting 
compounds) [145-156, 159]. Many MC-related 
mechanisms and molecules may play a role in 
immune surveillance against tumor growth. These 
include, among others, TNF, perforin/cytolysin, 
proteases, and IgE-dependent processes that lead to 
tumor cell destruction [272, 273]. Unfortunately, most 
such observations have been made in experimental 
models, and the actual net impact of MCs during 
tumor development in patients suffering from various 
malignancies remains unknown. It is also worth 
noting that chronic MC activation is not known to be 
associated with a lower or higher risk of human 
malignancies. 
Neoplastic Disorders of MCs and their 
Precursors 
The pathologic accumulation of MCs in the skin 
of patients with urticaria pigmentosa (UP) was first 
described by Paul Gerson Unna in 1887. Later, the 
term mastocytosis was proposed, based on the stable 
clinical course of most patients and the belief that the 
MC accumulations were reactive rather than 
neoplastic in nature (the suffix ‘osis’ is usually 
employed to describe benign/reactive expansions of 
leukocytes). This hypothesis was supported by the 
observation that the cutaneous lesions of 
mastocytosis, when manifested in early childhood, 
often disappeared during or shortly after puberty 
[274]. 
In 1949, Ellis described the first case of systemic 
mastocytosis (SM) with involvement of internal 
organs [275]. From this and other similar cases it was 
appreciated that mastocytosis in adults is a persistent 
and neoplastic disease that may be complicated by 
organ involvement or even organ damage. At 
approximately the same time, the first cases of MC 
leukemia (MCL) were described. Since then, a bone 
marrow biopsy has been regarded as a basic standard 
in the diagnostic evaluation of patients with 
suspected SM. 
A first comprehensive classification of 
mastocytosis was proposed by Karl Lennert and the 
Kiel group in 1979 [276]. In 1988, Travis et al. 
proposed a classification for systemic mast cell 
disease which introduced indolent, aggressive and 
associated hematologic disease categories [277]. In 
1991, Dean Metcalfe proposed a first consensus 
classification of mastocytosis [278]. The clonal nature 
of SM was confirmed by demonstrating that the 
involved cells (MCs and their precursors) exhibit the 
transforming KIT mutation D816V [279-281]. This 
mutation had been described as one of two activating 
KIT mutations in the HMC-1 mast cell line that was 
derived from a patient with MCL [282, 283]. Shortly 
afterwards, KIT mutation analysis was introduced as 
a major diagnostic test in patients with suspected SM. 
Between 1990 and 2000, specific morphologic, 
immunologic, and molecular features of neoplastic 
MCs were examined for their specificity and 
robustness. Based on such studies, criteria were 
proposed to make the diagnosis of SM and to support 
a related classification of mastocytosis [137]. This 
proposal serves as a basis of the WHO classification of 
mastocytosis [138, 139]. The most recent update of this 
classification divides the disease into cutaneous 
mastocytosis (CM), indolent SM (ISM), smoldering 
SM (SSM), SM with an associated hematologic 
neoplasm (SM-AHN), aggressive SM (ASM), MCL, 
and MC sarcoma (MCS) [138, 139]. We refer to the 
available literature for the details of the classification, 
and for the criteria of SM. However, it is essential to 
focus here on a few aspects related to the clinical 
impact of MCs in these disorders. 
First, it is important to recognize that patients 
with SM may or may not present with severe 
mediator-related symptoms. Patients who are 
suffering from such symptoms and require 
continuous treatment with anti-mediator-type drugs 
are labeled as SMSY [169]. In severe cases, a MCAS is 
almost always detected in these patients [168, 169]. 
Others suffering from SM also have an underlying 
hypertryptasemia (HAT). Another important point is 
that in pediatric patients, in whom the disease was 
long believed to be a ´reactive´ (non-neoplastic) 
process, the disorder is now regarded as a neoplastic 
condition, because in most cases activating (somatic 
or germline) mutations in KIT are detectable [284, 
285]. Remarkably, however, the presence of the 
D816V KIT mutation or other KIT mutations cannot 
predict the clinical course in pediatric CM. Rather, it is 
the presence of the typical (adult-like, i.e. small sized, 
monomorphic) form of the cutaneous lesions that 
helps predict persistence of pediatric mastocytosis 
into adulthood [286]. 
Another riddle regarding MCs in SM was the 
fact that the KIT D816V mutation is expressed in MCs 
in both indolent SM associated with a normal 
life-expectancy, as well as in MCs in advanced SM, 





including MCL where the survival time is usually 
very short [137-139, 279-281, 285]. In this regard, it is 
important to appreciate that KIT D816V acts as weak 
oncogene regarding proliferation but as a strong 
inducer of MC differentiation, maturation and 
survival, processes that are usually associated with 
reduced proliferation [287]. However, in a subset of 
patients with SM, KIT D816V can be detected in MCs, 
as well as in other hematopoietic lineages [288, 289]. 
Such multi-lineage involvement is typically found in 
smoldering SM and advanced SM and is of prognostic 
significance [290]. 
Moreover, several additional oncogenic 
mutations (apart from KIT mutations) have been 
detected and serve as new diagnostic and prognostic 
parameters in patients with advanced SM (SM-AHN, 
ASM or MCL) [291-295]. The current hypothesis is 
that these additional mutations (most commonly in: 
TET2, SRSF2, ASXL1, CBL, RUNX1, and RAS) act 
together with KIT D816V in advanced SM to trigger 
proliferation and survival of neoplastic MCs. The type 
and number of such additional mutations have a 
major impact on the prognosis (including overall 
survival and responses to therapy) of patients with 
SM [295]. For example, a particularly poor prognosis 
is found in patients who carry mutations in SRSF2, 
ASXL1, and RUNX1 (S/A/R-patients) [295]. It is also 
worth mentioning that most of these mutations are 
also found in other myeloid neoplasms (without SM) 
and that, among advanced SM patients, they are most 
frequently detected in SM-AHN. 
Taken together, the unique features of SM and 
the cell-specific evolution of MC progenitors and 
other cell lineages in advanced SM provide additional 
evidence that MCs form a separate myeloid lineage 
within the hematopoietic cell system. Moreover, 
despite expression of certain ´lymphoid´ antigens on 
neoplastic MCs, the progression-patterns seen in 
patients with SM-AHN confirm that MCs are best 
regarded as myeloid cells. In fact, in almost all 
patients with SM-AHN, the AHN portion of the 
disease manifests as a myeloid neoplasm, but only 
rarely as a lymphoid malignancy [41, 137-139]. 
New Treatment Concepts: Targeting of 
MC Growth and/or Activation 
During the past 3 decades, several different 
treatment approaches have been established for MC 
proliferative disorders and for conditions defined by 
MC activation. Whereas initial attempts to block MC 
growth in patients with advanced SM were based on 
treatment with conventional anti-neoplastic drugs, 
like interferon-alpha or cladribine [296, 297], more 
recent approaches are based on using validated drug 
targets [138, 298-302]. Considering the possibility of 
inducing MC deficiency by blocking MC 
development from their progenitors, the clinically 
most relevant targets identified so far are WT KIT 
(normal MCs) and the KIT mutant D816V that acts as 
a driver of MC development and differentiation in 
CM and SM [255, 283, 284, 287]. As mentioned before, 
imatinib is a strong KIT inhibitor and can induce an 
almost complete MC deficiency when administered 
continuously [125]. MC-depletion in subjects treated 
with imatinib takes about 2 years [125]. Application of 
such KIT inhibitors also may be of interest in the 
context of MC activation, atopic disorders or severe 
allergies. Indeed, a recent double-blind, placebo- 
controlled study in a small number of patients with 
severe asthma indicates that imatinib may be useful in 
this setting, although it is not clear to what extent the 
benefit observed was due to effects on MCs as 
opposed to other actions of the drug [298, 299]. 
However, the KIT D816V mutation confers 
imatinib resistance on neoplastic MCs [300, 301]. 
Therefore, novel KIT tyrosine kinase inhibitors have 
been developed for testing in preclinical and clinical 
studies. One of these drugs is midostaurin (PKC412), 
which blocks the kinase activity of wild type KIT, KIT 
D816V and several other clinically relevant KIT 
mutants [300, 301]. In addition, in contrast to most 
other KIT blockers, midostaurin inhibits SYK 
activation and several other IgE-receptor downstream 
targets; midostaurin thereby blocks MC activation 
and IgE-dependent mediator secretion in MCs and 
basophils [302]. 
In a first pilot patient with advanced SM, 
midostaurin was found to block the expansion of KIT 
D816V-mutated MCs [303]. More recently, 
midostaurin was administered to patients with 
advanced SM in a global, single arm, phase II trial. In 
this study, midostaurin was found to induce major 
and often durable clinical responses in many cases 
with advanced SM, including MCL [304]. Remarkably, 
many patients not only developed meaningful 
hematologic responses but also major responses in 
mediator-related symptoms and a substantial increase 
in their quality of life [304]. The latter effect of the 
drug may reflect its ability to suppress mediator 
release in MCs [302]. Based on these data, midostaurin 
was approved by the US Food and Drug 
Administration and the European Medicines Agency 
in 2017 for all subtypes of advanced SM [305]. In 
addition, midostaurin may be an interesting drug for 
patients with non-advanced SM in whom 
mediator-induced symptoms cannot be controlled by 
conventional anti-mediator type drugs. 
In addition to midostaurin, several other 
KIT-targeting drugs have been tested in the context of 
advanced SM [301]. Whereas some of them, like 





imatinib or masitinib, are unable to suppress the 
kinase activity of mutant KIT (especially D816V), 
others, like avapritinib or ripretinib, are potent 
inhibitors of KIT D816V and can block the growth of 
neoplastic progenitor cells [306]. As noted above, all 
of these inhibitors are candidates for evaluation in the 
context of allergic/atopic disorders and various 
immunologic or rheumatologic diseases where MC 
activation is thought to play an important role [298, 
307]. However, in these non-neoplastic diseases, the 
use of these agents must be carefully balanced against 
their side effects. It should also be kept in mind that 
some of the clinical effects and side effects of the 
‘KIT-targeting’ drugs may reflect actions on KIT 
expressed by cells other than MCs or on tyrosine 
kinases other than KIT. Other drugs act on various 
signaling or effector molecules downstream of KIT 
and/or downstream of the IgE receptor [308, 309]. The 
clinical efficacy of many of these agents is currently 
being explored in clinical trials. Finally, for patients 
with severe allergies and MCAS, and for those who 
are suffering from severe allergies, MCAS and/or 
additional aggravating MC conditions (like HAT 
and/or mastocytosis), application of antibodies 
removing IgE, such as omalizumab or ligelizumab, or 
targeting MC tryptase, may represent promising 
additional approaches [310-314]. Finally, a number of 
inhibitory receptors, such as Siglec-7, Siglec-8, or 
CD300a, have been identified on human MCs and are 
currently being validated for their role as therapeutic 
target sites [315-318]. 
Concluding Remarks and Future 
Perspectives 
Since their description and naming by Paul 
Ehrlich, MCs have been the subject of intensive 
research and have fascinated generations of scientists. 
Some of the riddles concerning the origin and 
functions of MCs have now been solved. MCs are 
hematopoietic cells derived from CD34+ stem cells, 
develop and survive under the influence of SCF, and 
can undergo neoplastic transformation based on 
acquiring gain-of-function mutations in the SCF 
receptor (KIT) gene and other critical target genes. 
Moreover, some of the mechanisms underlying MC 
activation in various disease states and related 
syndromes have been defined. Also, a variety of 
diagnostic markers and drug targets have been 
identified and have been successfully validated, and 
several drugs targeting MC expansion, MC activation, 
or both have been translated from preclinical testing 
into clinical applications. In advanced MC disorders, 
KIT appears to be a most promising target. Finally, 
diagnostic criteria for MC disorders, including 
mastocytosis and mast cell activation syndromes, 
have been established. 
However, many questions remain. For example, 
there is still debate about the possible roles of MCs in 
healthy tissues. Notably, the long-term MC-deficiency 
induced by persistent treatment with imatinib in 
humans has not yet been associated with a particular 
adverse phenotype. Also, in several pathologic 
conditions, it remains unknown whether MC 
activation may be useful, e.g., by enhancing repair 
processes, is harmful and leads to tissue damage, or, 
depending on the circumstances, may contribute to 
either outcome. Finally, it remains unknown which 
KIT-independent molecular pathways and molecules 
play the most decisive role in the progression of mast 
cell neoplasms. We trust that future MC research will 
provide answers to such questions, leading to a better 
understanding of MC biology in health and disease, 
as well as to the development of new and better 
diagnostics and better treatments for patients 
suffering from MCAS, advanced MC neoplasms or 
other MC-dependent pathologies. 
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